Kura Oncology (NASDAQ:KURA) Shares Gap Up – Here’s Why

Shares of Kura Oncology, Inc. (NASDAQ:KURA) gapped up prior to trading on Tuesday . The stock had previously closed at $17.56, but opened at $18.30. Kura Oncology shares last traded at $18.68, with a volume of 40,820 shares.

Analyst Ratings Changes

KURA has been the topic of several analyst reports. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. StockNews.com upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Wednesday. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company’s 50 day moving average price is $18.63 and its 200-day moving average price is $19.97. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -7.52 and a beta of 0.86.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. nVerses Capital LLC purchased a new position in shares of Kura Oncology in the third quarter worth approximately $25,000. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 1st quarter valued at $110,000. Quarry LP purchased a new position in shares of Kura Oncology during the 2nd quarter valued at $196,000. Entropy Technologies LP acquired a new position in shares of Kura Oncology in the first quarter worth $218,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Kura Oncology by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.